Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Peterson Wealth Services

Peterson Wealth Services lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 9.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,128 shares of the medical research company’s stock after selling 330 shares during the period. Peterson Wealth Services’ holdings in Edwards Lifesciences were worth $239,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Castleview Partners LLC acquired a new position in shares of Edwards Lifesciences during the first quarter worth $25,000. Compass Wealth Management LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at $31,000. Turtle Creek Wealth Advisors LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at $34,000. Jackson Grant Investment Advisers Inc. acquired a new position in Edwards Lifesciences in the third quarter valued at $38,000. Finally, Janiczek Wealth Management LLC boosted its stake in Edwards Lifesciences by 108.6% in the third quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company’s stock valued at $40,000 after acquiring an additional 303 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

EW has been the subject of several research analyst reports. Stifel Nicolaus upped their price objective on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research note on Wednesday, February 7th. Wells Fargo & Company upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective for the company in a research note on Friday, February 2nd. Truist Financial upped their target price on shares of Edwards Lifesciences from $78.00 to $84.00 and gave the company a “buy” rating in a report on Friday, December 22nd. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. Finally, Mizuho upped their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, April 11th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $91.73.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Heisz Leslie Stone sold 7,056 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $86.45, for a total transaction of $609,991.20. Following the completion of the sale, the director now owns 26,980 shares in the company, valued at $2,332,421. The disclosure for this sale can be found here. Over the last three months, insiders have sold 194,004 shares of company stock worth $17,166,254. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

NYSE EW traded down $0.54 during trading hours on Thursday, hitting $86.70. 992,292 shares of the stock were exchanged, compared to its average volume of 3,835,127. The company has a market cap of $52.19 billion, a price-to-earnings ratio of 37.93, a price-to-earnings-growth ratio of 4.46 and a beta of 1.05. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The stock has a 50-day moving average of $90.12 and a 200 day moving average of $78.14. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.50 billion. During the same period in the prior year, the company posted $0.64 earnings per share. The firm’s revenue for the quarter was up 13.3% on a year-over-year basis. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.